An analysis of harms reporting in systematic reviews regarding ketorolac for management of perioperative pain

Ref ID 922
First Author J. Modi
Journal BRITISH JOURNAL OF ANAESTHESIA
Year Of Publishing 2022
URL https://www.bjanaesthesia.org/article/S0007-0912(22)00449-4/fulltext
Keywords Harms
Pharmacological
Pain
Low methodological quality
Problem(s) Selective reporting of harms / safety / adverse events / side effects
Low methodological (AMSTAR) quality
Number of systematic reviews included 28
Summary of Findings From 28 systematic reviews of ketorolac tromethamine to minimise postoperative opioid requirements indexed across MEDLINE (PubMed and Ovid), Embase, Epistemonikos, and the Cochrane Database of Systematic Reviews up to May 2022. Seven of the included systematic reviews (7/28, 25%) reported no harms and 17 systematic reviews (17/28, 60.7%) reported ≤50% of harms items. A significant association was found between completeness of harms reporting and whether harms were specified as a primary outcome (P<0.001). Methodological quality (AMSTAR-2) in 22 systematic reviews was appraised as ‘critically low’ (22/28, 78.6%), 5 as ‘low’ (5/28, 17.9%), and 1 as ‘high’ (1/28, 3.6%).
Did the article find that the problem(s) led to qualitative changes in interpretation of the results? Not Applicable
Are the methods of the article described in enough detail to replicate the study? Yes